nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

24.11.2017 | Editorial Commentary

Invited editorial for the paper by Silvoniemi et al. “Repeatability of tumor hypoxia imaging using [¹⁸F]EF5 PET/CT in head and neck cancer.” in this issue of EJNMMI

verfasst von: Cameron J. Koch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Silvoniemi A, Suilamo S, Laitinem T, Forsback S, Loyttyniemi E, Vaittinen S, Solin O, Gronroos TJ, Minn H. Repeatability of tumour hypoxia imaging using [¹⁸F]EF5 PET/CT in head and neck cancer. Eur J Nuc Med Molecular Imaging 2018.

Ziemer LS, Koch CJ, Maity A, Pook-Magarelli D, Horan A-M, Evans SM. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia. 2001;3:500–8.CrossRefPubMedPubMedCentral

Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, et al. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys. 2007;69:1024–31.CrossRefPubMedPubMedCentral

Komar G, Lehtio K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. Prognostic value of tumour blood flow,[¹⁸F]-EF5 and [¹⁸F]-FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nuc Med Mol Imaging. 2014;41:2042–50.CrossRef

Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibiliy of intratumor distribution of ¹⁸F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–42.CrossRefPubMedPubMedCentral

Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by ¹⁸F-Fluoromisonidazole PET for head and neck cancer. J Nuc Med. 2013;54:201–7.CrossRef

Zegers CML, van Elmpt W, Szardenings K, Kolb H, Waxman A, Subramanian RM, et al. Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. Eur J Nuc Med Mol Imaging. 2015;42:1840–9.CrossRef

Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, et al. Biodistribution and dosimetry of ¹⁸F-EF5 in cancer patients with preliminary comparison of ¹⁸F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nuc Med Mol Img. 2010;37:2048–59.CrossRef

Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, et al. Radiation dosimetry and biodistribution of the hypoxia tracer ¹⁸F-EF5 in oncologic patients. Cancer Bioth Radiopharmaceut. 2012;27:412–9.CrossRef

10.

Raleigh JA, Koch CJ. The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol. 1990;40:2457–64.CrossRefPubMed

11.

Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Brit J Radiol. 1979;52:650–6.CrossRefPubMed

12.

Trotter MJ, Chaplin DJ, Durand RE, Olive PL. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys. 1989;16:931–4.CrossRefPubMed

13.

Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 2008;68:5812–9.CrossRefPubMed

14.

Rofstad EK, Gaustad JV, Egeland TAM, Mathiesen B, Galappanthi K. Tumors exposed to acute cycling hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer. 2010;127:1535–46.CrossRefPubMed

15.

Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos JT, Forsback S, et al. ¹⁸F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nuc Med. 2008;49:1–8.CrossRef

16.

Koch CJ, Evans SM. In: Molecular Imaging Probes for Cancer Research, X Chen ed, World Scientific, Singapore, 2012; Chapter 10: "Non-Invasive Imaging of Hypoxia - Challenges and Opportunities" pp 286–315.

17.

Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, et al. Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors. Tumor Microenv & Ther. 2012b;1:1–13.CrossRef

18.

Cascieri JJ, Graham MM, Rasey JS. A modelling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys. 1995;22:1127–39.CrossRef

Titel: Invited editorial for the paper by Silvoniemi et al. “Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer.” in this issue of EJNMMI
verfasst von: Cameron J. Koch
Publikationsdatum: 24.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3889-8

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer

The prognostic value of 18F–FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases

Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer

Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

Patterns of bone tracer uptake on SPECT-CT in symptomatic and asymptomatic patients with primary total hip arthroplasty